Finasteride and Feminising Hormone Therapy

Evidence Note

What is the question?

Finasteride, and its more potent relative dutasteride, are 5α-reductase inhibitors: they block the enzyme that converts testosterone into dihydrotestosterone (DHT), the more potent androgen that drives male-pattern scalp hair loss and much body and facial hair growth. The question is whether adding one of them on top of feminising hormone therapy — which already lowers testosterone — does anything worthwhile.

What does the evidence say?

With effective suppression, DHT is usually already low. When feminising therapy suppresses testosterone effectively, circulating DHT is also expected to fall substantially. A drug whose main action is to lower DHT has less left to do when DHT is already low — so for many people who are well suppressed, a 5α-reductase inhibitor may add little.

Where it might still help. The clearest potential role is scalp hair: androgenetic hair loss that began before therapy, or thinning that continues because testosterone is not fully suppressed. There, additional DHT suppression may help preserve existing hair and, in some people, support partial regrowth. Some clinicians also prescribe finasteride or dutasteride because scalp hair follicles can remain sensitive to very low androgen concentrations, although whether this meaningfully improves outcomes beyond good testosterone suppression has not been established in trans women. What evidence exists is drawn largely from cisgender men with male-pattern hair loss, not measured in trans women.

It is not a feminising drug. Finasteride does not itself feminise the body or raise oestrogen concentrations; it is a hair-directed add-on, not part of the hormone regimen itself.

The trans-specific evidence is thin. Most finasteride data come from cisgender men treated for hair loss or prostate enlargement. Its specific added value in trans women already on modern feminising therapy has barely been studied.

How strong is the evidence?

Weak for trans women, despite a well-established mechanism. The mechanism is well understood, and finasteride clearly benefits androgenetic alopecia in cisgender men. What remains uncertain is how much additional benefit it provides once testosterone is already well suppressed in trans women.

Where are the uncertainties?

Whether a 5α-reductase inhibitor improves outcomes on top of effective suppression is not established in trans women. Separately, there is a debated signal linking finasteride to low mood, anxiety and depressive symptoms in some people; how large this is, and whether the drug is the cause, remain uncertain — but it is worth being aware of rather than dismissing.

On well-suppressed feminising therapy, a drug whose main action is to lower DHT has less left to do.

What does this mean for practice?

This is information, not a recommendation to start or stop anything. For most people who are well suppressed on feminising therapy, a 5α-reductase inhibitor is not routinely added. Where scalp hair is a specific goal — particularly if hair loss predated therapy, or if testosterone is not fully suppressed — it is a reasonable thing to raise with a clinician, weighing the possible hair benefit against the mood signal and the person’s whole picture. As with everything here, it is a decision made with a clinician, not from a note.